Recent research is shedding light on the crucial role of B cells in the fight against cancer, opening exciting new avenues for therapeutic development, according to Stefano Gullà, Chief Scientific Officer at Kling Biotherapeutics.  Cancer immunotherapies have been raising the bar for standard of care in oncology for more than a decade but equally, their […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!